Akash Tewari
Stock Analyst at Jefferies
(1.58)
# 3,411
Out of 5,030 analysts
60
Total ratings
33.33%
Success rate
-1.69%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $73.09 | +31.34% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $578.05 | +43.76% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $12.54 | +107.34% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $9.52 | +5.04% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $43.63 | +55.86% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $53.29 | +78.27% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $105.14 | +42.67% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $6.49 | +146.53% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $140.09 | +34.91% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $24.52 | +226.26% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $802.83 | +26.43% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $30.26 | +65.23% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $55.15 | +35.99% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $22.47 | +37.96% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $24.51 | +59.12% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $11.01 | +63.49% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $843.66 | -39.19% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.41 | +114.03% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $84.79 | +47.42% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $18.40 | -40.22% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.81 | +839.23% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $58.44 | +28.34% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $438.90 | -65.60% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $39.25 | -28.66% | 3 | Oct 7, 2021 |
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $73.09
Upside: +31.34%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $578.05
Upside: +43.76%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $12.54
Upside: +107.34%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $9.52
Upside: +5.04%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $43.63
Upside: +55.86%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $53.29
Upside: +78.27%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $105.14
Upside: +42.67%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $6.49
Upside: +146.53%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $140.09
Upside: +34.91%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $24.52
Upside: +226.26%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $802.83
Upside: +26.43%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $30.26
Upside: +65.23%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $55.15
Upside: +35.99%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $22.47
Upside: +37.96%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $24.51
Upside: +59.12%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $11.01
Upside: +63.49%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $843.66
Upside: -39.19%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $8.41
Upside: +114.03%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $84.79
Upside: +47.42%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $18.40
Upside: -40.22%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.81
Upside: +839.23%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $58.44
Upside: +28.34%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $438.90
Upside: -65.60%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $39.25
Upside: -28.66%